ClinicalTrials.gg
CompletedNCT06973005CRIOLLOUpdated Jul 24, 2025

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

A Phase 1 interventional study of AZD2389 and Midazolam in Advanced Chronic Liver Disease and Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
9th of 11
16 · median 40
Started
2025
with 3 others
Phase 1
5 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 9th largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 1, and was the 8th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.

Read the detailed description

This study is an open-label, fixed sequence, 3-period, drug-drug interaction (DDI) study in healthy participants performed at a single Clinical Unit.

The study will comprise:

  • A Screening Period of maximum 28 days.
  • A Treatment Phase, separated into 3 different periods. Period 1 (Day -2 to Day 4): Participants will receive midazolam and caffeine in combination on Day 1. Participants will receive bupropion on Day 2.

Period 2 (Day 5 to Day 13): Participants will receive AZD2389 for 9 days. Period 3 (Day 14 to Day 18): Participants will first receive AZD2389 with midazolam and caffeine in combination on Day 14. On Day 15, participants will first receive AZD2389 with bupropion. On Days 16 and 17, participants will receive AZD2389.

- A final Follow-up Visit, 7 to 14 days after the last AZD2389 PK sample is taken in Period 3.

03

Conditions studied

  • Advanced Chronic Liver Disease
  • Healthy Participants

Browse trials for

Keywords

  • Hepatic Fibrosis
  • FAP inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study-specific procedures.
  • Participants with suitable veins for cannulation or repeated venipuncture.
  • Have a (BMI) between 18 and 32 kilograms per meter squared (kg/m2) inclusive and weigh at least 50 kilograms (kg) at Screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in clinical chemistry, coagulation, hematology, or urinalysis results.
  • Any positive result at the Screening Visit for serum surface antigen (HBsAg), hepatitis B core antibody (HBcAb), virus (HCV), or (HIV).
  • Abnormal vital signs, after 10 minutes supine rest, at the Screening Visit and/or admission to the Clinical Unit (Day -2).
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead safety .
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • History of hypersensitivity to DPP4 inhibitors, as judged by the investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to DPP4 inhibitors.
  • History of severe dermatological disorders, eg, bullous pemphigoid or Stevens-Johnson syndrome, as judged by the investigator.
  • Participants who have previously received AZD2389 within the last 12 months prior to the Screening Visit.
  • Known hypersensitivity or previous adverse events associated with midazolam, caffeine, or bupropion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    In Period 1, participants will receive midazolam and caffeine in combination on Day 1. Participants will receive bupropion on Day 2. In Period 2, participants will receive AZD2389 for 9 days from Day 5 to Day 13. In Period 3, participants will first receive AZD2389 with midazolam and caffeine in combination on Day 14. On Day 15, participants will first receive AZD2389 with bupropion. On Days 16 and 17, participants will receive AZD2389.

    Drug: AZD2389 · Drug: Midazolam · Drug: Caffeine · Drug: Bupropion

Interventions

  • Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.

  • Single oral dose on: * Day 1 (co-administered with caffeine) * Day 14 (co-administered with caffeine and AZD2389)

  • Single oral dose on: * Day 1 (co-administered with midazolam) * Day 14 (co-administered with midazolam and AZD2389)

  • Single oral dose on: * Day 2 (alone) * Day 15 (co-administered with AZD2389)

06

What researchers measure

Primary outcomes

  1. Ratio of treatment to reference based on Cmax (RCmax)

    To assess the PK parameter RCmax for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  2. Ratio of treatment to reference based on AUCinf (RAUCinf)

    To assess the PK parameter RAUCinf for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  3. Ratio of treatment to reference based on AUClast (RAUClast)

    To assess the PK parameter RAUClast for midazolam, caffeine, and bupropion in combination with AZD2389 compared to midazolam, caffeine, and bupropion alone.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  4. Ratio of area under concentration-curve from time 0 to 24 hours post-dose (AUC0-24)

    To assess the PK parameter ratio of AUC0-24 for caffeine in combination with AZD2389 compared to caffeine alone.

    Time frame: Period 1: Days 1-3; Period 3: Days 15-18.

Secondary outcomes

  1. Apparent total body clearance (CL/F)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  2. Apparent volume of distribution based on the terminal phase (Vz/F)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  3. Terminal elimination half-life (t1/2λz)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  4. Terminal rate constant (λz)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  5. Time to reach maximum observed concentration (tmax)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  6. Maximum observed concentration (Cmax)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  7. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  8. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To describe the plasma PK of midazolam, caffeine, bupropion, and their metabolites (1'-OH-midazolam, paraxanthine, and hydroxy-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389. To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  9. AUC0-24

    To describe the plasma PK of caffeine and its metabolites (paraxanthine) when caffeine is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-3; Period 3: Days 15-18.

  10. RCmax

    To assess the RCmax for the metabolites of midazolam, caffeine, and bupropion (1'-OH-midazolam, paraxanthine, OH-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  11. RAUCinf

    To assess the RAUCinf for the metabolites of midazolam, caffeine, and bupropion (1'-OH-midazolam, paraxanthine, OH-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  12. RAUClast

    To assess the RAUClast for the metabolites of midazolam, caffeine, and bupropion (1'-OH-midazolam, paraxanthine, OH-bupropion) when midazolam, caffeine, or bupropion is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  13. Ratio of treatment to reference based on AUC0-24 (RAUC0-24)

    To assess the RAUC0-24 for the metabolites of caffeine, (paraxanthine) when caffeine is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-3; Period 3: Days 15-18.

  14. Metabolite to parent ratio of the AUCinf

    To assess the metabolite to parent ratio of the AUCinf for midazolam, caffeine, and bupropion.

    Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.

  15. Metabolite to parent ratio of the AUC0-24

    To assess the metabolite to parent ratio of the AUC0-24 for caffeine and its metabolite (paraxanthine) when caffeine is administered alone and in combination with AZD2389.

    Time frame: Period 1: Days 1-3; Period 3: Days 15-18.

  16. Area under concentration-time curve in the dose interval (AUCtau)

    To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 2: Days 5-13; Period 3: Day 14.

  17. Observed lowest concentration before the next dose is administered (Ctrough)

    To describe the plasma PK of AZD2389 after multiple dose administration.

    Time frame: Period 2: Days 5-13; Period 3: Day 14.

  18. Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of multiple oral doses of AZD2389 alone or in combination with midazolam, caffeine and bupropion in healthy participants.

    Time frame: Only SAE: -30 to -3 to Day -1. AE and SAE: From Day 1 to Follow-up/Early Termination Visit (Days 25-32)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2025, 2 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 15, 2025
StartActual
May 8, 2025
Primary completionActual
Jul 18, 2025
CompletionActual
Jul 18, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973005
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 15, 2025
Start date
May 8, 2025
Primary completion
Jul 18, 2025
Completion
Jul 18, 2025
Last update
Jul 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion